Webinar on Monday 20th June 2022 – 16.30-17.30 HRS (CET)
Muvon Therapeutics have developed a highly innovative technology, as described below, offering patients a minimally invasive, low-risk procedure (according to phase I data) in an outpatient setting. Potentially this procedure could prove a life changer and be long-lasting. The results still need to be corroborated in further clinical trials. So many patients suffer in silence and accept their condition as part of the ageing process. Although incontinence is a common condition, it is certainly not normal and nowadays many treatment options are available, however none of them offering functional regeneration. This new technology offers a safe and effective treatment for stress urinary incontinence in women who are unsatisfied with conservative measures and are searching for treatments other than for example annual bulking agent injections or invasive surgeries. Furthermore, by regenerating the muscle tissue, it is tackling the underlying cause, namely the damaged urinary sphincter muscle. Implantation of foreign materials or invasive surgeries are no longer necessary, nor does this new technology require hospitalization or cause any safety concerns. MUVON Therapeutics’ multidisciplinary and visionary team is determined and highly motivated to provide this therapy for patients, focusing on patient needs and obtaining robust feedback during the therapy development stage.
Webinar on Monday 20th June 2022 – 16.30-17.30 HRS (CET)
Muvon Therapeutics have developed a highly innovative technology, as described below, offering patients a minimally invasive, low-risk procedure (according to phase I data) in an outpatient setting. Potentially this procedure could prove a life changer and be long-lasting. The results still need to be corroborated in further clinical trials. So many patients suffer in silence and accept their condition as part of the ageing process. Although incontinence is a common condition, it is certainly not normal and nowadays many treatment options are available, however none of them offering functional regeneration. This new technology offers a safe and effective treatment for stress urinary incontinence in women who are unsatisfied with conservative measures and are searching for treatments other than for example annual bulking agent injections or invasive surgeries. Furthermore, by regenerating the muscle tissue, it is tackling the underlying cause, namely the damaged urinary sphincter muscle. Implantation of foreign materials or invasive surgeries are no longer necessary, nor does this new technology require hospitalization or cause any safety concerns. MUVON Therapeutics’ multidisciplinary and visionary team is determined and highly motivated to provide this therapy for patients, focusing on patient needs and obtaining robust feedback during the therapy development stage.